Cedars-Sinai, Samuel Oschin Cancer CenterLos Angeles, California, United States
Disclosure information not submitted.
Paper 26 - A FIRST-IN-HUMAN STUDY OF CDK9 INHIBITOR KB-0742 DEMONSTRATES PRELIMINARY EVIDENCE OF CLINICAL ACTIVITY IN TRANSCRIPTIONALLY ADDICTED SARCOMAS
Thursday, November 2, 20234:00 PM – 5:30 PM